Hans Eriksson

3.4k total citations
71 papers, 2.2k citations indexed

About

Hans Eriksson is a scholar working on Psychiatry and Mental health, Pharmacology and Experimental and Cognitive Psychology. According to data from OpenAlex, Hans Eriksson has authored 71 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Psychiatry and Mental health, 36 papers in Pharmacology and 20 papers in Experimental and Cognitive Psychology. Recurrent topics in Hans Eriksson's work include Treatment of Major Depression (35 papers), Schizophrenia research and treatment (24 papers) and Bipolar Disorder and Treatment (24 papers). Hans Eriksson is often cited by papers focused on Treatment of Major Depression (35 papers), Schizophrenia research and treatment (24 papers) and Bipolar Disorder and Treatment (24 papers). Hans Eriksson collaborates with scholars based in United States, Sweden and Germany. Hans Eriksson's co-authors include Catherine Datto, Mary Hobart, William H. Carson, Raymond Sanchez, Robert D. McQuade, Aleksandar Skuban, Margaretta Nyilas, Johan Szamosi, Peter Zhang and Michael E. Thase and has published in prestigious journals such as American Journal of Psychiatry, Biochemical and Biophysical Research Communications and Journal of Affective Disorders.

In The Last Decade

Hans Eriksson

70 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hans Eriksson United States	25	1.2k	1.1k	562	360	205	71	2.2k
I. Gergel United States	11	936 0.8×	953 0.9×	621 1.1×	400 1.1×	116 0.6×	28	2.3k
Emanuel Severus Germany	22	1.3k 1.1×	589 0.6×	340 0.6×	305 0.8×	284 1.4×	69	2.2k
Markus Dold Austria	24	970 0.8×	823 0.8×	571 1.0×	403 1.1×	498 2.4×	67	2.2k
Arif Khan United States	20	1.3k 1.0×	827 0.8×	355 0.6×	631 1.8×	159 0.8×	42	2.4k
Willie Earley United States	26	1.6k 1.3×	690 0.7×	245 0.4×	238 0.7×	229 1.1×	82	2.0k
Matthias J. Müller Germany	28	1.0k 0.8×	368 0.3×	322 0.6×	304 0.8×	118 0.6×	61	1.9k
Anjana Bose United States	19	595 0.5×	931 0.9×	623 1.1×	256 0.7×	174 0.8×	28	1.5k
Suresh Durgam United States	27	1.9k 1.6×	605 0.6×	270 0.5×	391 1.1×	297 1.4×	94	2.4k
Pierre V. Trân United States	17	1.5k 1.2×	616 0.6×	175 0.3×	297 0.8×	120 0.6×	28	1.9k
S.H. Hamilton United States	18	2.4k 1.9×	725 0.7×	201 0.4×	483 1.3×	150 0.7×	41	3.0k

Countries citing papers authored by Hans Eriksson

Since Specialization

Citations

This map shows the geographic impact of Hans Eriksson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans Eriksson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans Eriksson more than expected).

Fields of papers citing papers by Hans Eriksson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans Eriksson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans Eriksson. The network helps show where Hans Eriksson may publish in the future.

Co-authorship network of co-authors of Hans Eriksson

This figure shows the co-authorship network connecting the top 25 collaborators of Hans Eriksson. A scholar is included among the top collaborators of Hans Eriksson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans Eriksson. Hans Eriksson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Marder, Stephen R., Hans Eriksson, Yudong Zhao, & Mary Hobart. (2020). Post hoc analysis of a randomised, placebo-controlled, active-reference 6-week study of brexpiprazole in acute schizophrenia. Acta Neuropsychiatrica. 32(3). 153–158. 11 indexed citations

Newcomer, John W., et al.. (2019). Changes in Metabolic Parameters and Body Weight in Patients With Major Depressive Disorder Treated With Adjunctive Brexpiprazole. The Journal of Clinical Psychiatry. 80(6). 6 indexed citations

Simblett, Sara, Faith Matcham, Sara Siddi, et al.. (2018). Barriers to and Facilitators of Engagement With mHealth Technology for Remote Measurement and Management of Depression: Qualitative Analysis. JMIR mhealth and uhealth. 7(1). e11325–e11325. 73 indexed citations

Thase, Michael E., James M. Youakim, Aleksandar Skuban, et al.. (2015). Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder. The Journal of Clinical Psychiatry. 76(9). 1224–1231. 145 indexed citations

Thase, Michael E., James M. Youakim, Aleksandar Skuban, et al.. (2015). Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants. The Journal of Clinical Psychiatry. 76(9). 1232–1240. 136 indexed citations

Möller, Hans‐Jürgen, Koen Demyttenaere, Bengt Olausson, et al.. (2015). Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy. The World Journal of Biological Psychiatry. 16(7). 483–501. 24 indexed citations

Khan, Sajjad, Dennis A. Revicki, Mariam Hassan, et al.. (2015). Assessing the Reliability and Validity of the Sheehan Irritability Scale in Patients With Major Depressive Disorder. The Journal of Clinical Psychiatry. 77(8). 1080–1086. 6 indexed citations

Weisler, Richard H., Stuart Montgomery, Willie Earley, Johan Szamosi, & Hans Eriksson. (2014). Extended Release Quetiapine Fumarate in Patients With Major Depressive Disorder. The Journal of Clinical Psychiatry. 75(5). 520–527. 7 indexed citations

Bourin, Michel, Emanuel Severus, Juan Schronen, et al.. (2014). Lithium as add-on to quetiapine XR in adult patients with acute mania: a 6-week, multicenter, double-blind, randomized, placebo-controlled study. International Journal of Bipolar Disorders. 2(1). 14–14. 20 indexed citations

10.

Thase, Michael E., Stuart Montgomery, George I. Papakostas, et al.. (2013). Quetiapine XR monotherapy in major depressive disorder. International Clinical Psychopharmacology. 28(3). 113–120. 5 indexed citations

11.

Katila, Heikki, et al.. (2013). Randomized, Double-Blind Study of the Efficacy and Tolerability of Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Elderly Patients with Major Depressive Disorder. American Journal of Geriatric Psychiatry. 21(8). 769–784. 41 indexed citations

12.

Trivedi, Madhukar H., Borwin Bandelow, Koen Demyttenaere, et al.. (2013). Evaluation of the effects of extended release quetiapine fumarate monotherapy on sleep disturbance in patients with major depressive disorder: a pooled analysis of four randomized acute studies. The International Journal of Neuropsychopharmacology. 16(8). 1733–1744. 22 indexed citations

13.

Chue, Pierre, Ashok Malla, Roch-Hugo Bouchard, et al.. (2013). The long-term clinical benefit and effectiveness of switching to once-daily quetiapine extended release in patients with schizophrenia. Current Medical Research and Opinion. 29(3). 227–239. 8 indexed citations

14.

Locklear, Julie, et al.. (2011). PMH71 The Impact of Once-Daily Extended-Release Quetiapine Fumarate (Quetiapine XR) on Length and Costs of Hospitalisation of Patients with Schizophrenia or Bipolar Disorder. Value in Health. 14(7). A299–A299. 2 indexed citations

15.

Bonafede, Machaon, et al.. (2011). PMH72 The Impact of Once-Daily Extended-Release Quetiapine Fumarate (Quetiapine XR) on Length of Hospitalisation of Patients with Acute Bipolar Mania. Value in Health. 14(7). A300–A300. 2 indexed citations

16.

Merideth, Charles, et al.. (2011). Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder. International Clinical Psychopharmacology. 27(1). 40–54. 57 indexed citations

17.

Liebowitz, Michael R., Raymond W. Lam, Ulla Lepola, et al.. (2010). Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depression and Anxiety. 27(10). 964–976. 69 indexed citations

18.

Bauer, Michael, et al.. (2010). A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. Journal of Affective Disorders. 127(1-3). 19–30. 65 indexed citations

19.

Weisler, Richard H., et al.. (2009). Extended Release Quetiapine Fumarate Monotherapy for Major Depressive Disorder: Results of a Double-Blind, Randomized, Placebo-Controlled Study. CNS Spectrums. 14(6). 299–313. 89 indexed citations

20.

Datto, Catherine, Lovisa Berggren, Jitendra Patel, & Hans Eriksson. (2009). Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: A randomized, double-blind, crossover study in healthy adult subjects. Clinical Therapeutics. 31(3). 492–502. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact